J&J Vaccine Pause Is Appropriate, Mayo Clinic's Poland Says

The transcript discusses the importance of vaccine safety surveillance in the US, highlighting its ability to detect rare risks. It addresses public misunderstanding of background rates of clotting syndromes and compares the uptake of the J&J vaccine to AstraZeneca in Europe. The discussion includes potential immune-mediated clotting risks associated with the vaccine and the need to evaluate these risks against the background rate. The process of gathering information and working with regulators like the FDA and EU to assess risk levels is also covered.

What factors are associated with the blood clotting issues observed after vaccination?

What is the relationship between COVID-19 hospitalization and the development of blood clots?